Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, December 4, 2025 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage ...
Geneva, Switzerland, April 6, 2022-Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, ...
Geneva, Switzerland, December 1, 2025 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on ...
Please provide your email address to receive an email when new articles are posted on . Change from baseline in gait variability did not differ between groups, regardless of cognitive load. Treatment ...
News-Medical.Net on MSN
Mapping SV2A drug binding offers a path to better epilepsy treatments
A multi-institute team led by St. Jude Children's Research Hospital and UT Southwestern Medical Center investigators ...
A multi-institute team led by St. Jude Children's Research Hospital and UT Southwestern Medical Center investigators established for the first time how certain drugs used to treat epilepsy affect ...
A publication from Acta Pharmaceutica Sinica B discusses allosteric modulation of G protein-coupled receptors as a novel therapeutic strategy in neuropathic pain. Neuropathic pain is a debilitating ...
Ranjan K. Singh, Ahmed Soliman, Giambattista Guaitoli, Eliza Störmer, Felix von Zweydorf, Thomas Dal Maso, Asmaa Oun, Laura Van Rillaer, Sven H. Schmidt, Deep ...
Proceedings of the National Academy of Sciences of the United States of America, Vol. 119, No. 16 (April 19, 2022), pp. 1-10 (10 pages) Allosteric modulators of G-protein-coupled receptors (GPCRs) ...
Using cryo-electron microscopy, researchers have visualized how widely used epilepsy drugs bind and reshape the neuronal ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results